EP4100514A4 - POXVIRUS-BASED VECTORS PRODUCED BY NATURAL OR SYNTHETIC DNA AND THEIR USES - Google Patents

POXVIRUS-BASED VECTORS PRODUCED BY NATURAL OR SYNTHETIC DNA AND THEIR USES Download PDF

Info

Publication number
EP4100514A4
EP4100514A4 EP21750239.2A EP21750239A EP4100514A4 EP 4100514 A4 EP4100514 A4 EP 4100514A4 EP 21750239 A EP21750239 A EP 21750239A EP 4100514 A4 EP4100514 A4 EP 4100514A4
Authority
EP
European Patent Office
Prior art keywords
natural
synthetic dna
vectors produced
poxvirus vectors
poxvirus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21750239.2A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP4100514A2 (en
Inventor
Don J. Diamond
Felix WUSSOW
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
City of Hope
Original Assignee
City of Hope
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by City of Hope filed Critical City of Hope
Publication of EP4100514A2 publication Critical patent/EP4100514A2/en
Publication of EP4100514A4 publication Critical patent/EP4100514A4/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
    • A61K39/001151—Apoptosis related proteins, e.g. survivin or livin p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24151—Methods of production or purification of viral material
    • C12N2710/24152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/50—Vectors for producing vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
EP21750239.2A 2020-02-03 2021-02-02 POXVIRUS-BASED VECTORS PRODUCED BY NATURAL OR SYNTHETIC DNA AND THEIR USES Pending EP4100514A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062969628P 2020-02-03 2020-02-03
US202063113803P 2020-11-13 2020-11-13
PCT/US2021/016247 WO2021158565A2 (en) 2020-02-03 2021-02-02 Poxvirus-based vectors produced by natural or synthetic dna and uses thereof

Publications (2)

Publication Number Publication Date
EP4100514A2 EP4100514A2 (en) 2022-12-14
EP4100514A4 true EP4100514A4 (en) 2024-06-12

Family

ID=77200801

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21750239.2A Pending EP4100514A4 (en) 2020-02-03 2021-02-02 POXVIRUS-BASED VECTORS PRODUCED BY NATURAL OR SYNTHETIC DNA AND THEIR USES

Country Status (10)

Country Link
EP (1) EP4100514A4 (enExample)
JP (2) JP2023512294A (enExample)
KR (1) KR20220148823A (enExample)
CN (1) CN115397998A (enExample)
AU (2) AU2021217073A1 (enExample)
BR (1) BR112022014738A2 (enExample)
CA (1) CA3168836A1 (enExample)
IL (1) IL294926A (enExample)
MX (1) MX2022009200A (enExample)
WO (1) WO2021158565A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3167052A1 (en) 2020-02-14 2021-08-19 Mary Jo Hauser Vaccines and uses thereof to induce an immune response to sars-cov2
EP4153228A4 (en) 2020-05-17 2024-07-10 City of Hope CORONAVIRUS VACCINES BASED ON SYNTHETIC MODIFIED ANKARA VACCINE (SMVA) VIRUS
BR112023015467A2 (pt) 2021-02-02 2023-10-10 Geovax Inc Vetor viral de vaccinia ankara recombinante modificado, métodos para aumentar uma resposta imunológica a um antígeno alvo em um paciente e para prevenir, tratar ou induzir uma resposta imunológica contra um antígeno alvo, e, composição farmacêutica
CN115433741A (zh) * 2022-06-23 2022-12-06 广西大学 盖他病毒为载体表达报告蛋白的重组病毒的构建方法
CN118240879A (zh) * 2023-11-01 2024-06-25 上海市重大传染病和生物安全研究院 骨架质粒、重组质粒以及猴痘病毒颗粒和应用
CN119506355B (zh) * 2025-01-15 2025-10-17 中国人民解放军军事科学院军事医学研究院 一种用于重组痘病毒包装的载体系统及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019213452A1 (en) * 2018-05-02 2019-11-07 David Evans Synthetic chimeric vaccinia virus

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019213452A1 (en) * 2018-05-02 2019-11-07 David Evans Synthetic chimeric vaccinia virus

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FRANZISKA KUGLER: "Generation of recombinant MVA-norovirus: a comparison study of bacterial artificial chromosome- and marker-based systems", VIROLOGY JOURNAL, vol. 16, no. 1, 9 August 2019 (2019-08-09), GB, XP093158639, ISSN: 1743-422X, Retrieved from the Internet <URL:http://link.springer.com/article/10.1186/s12985-019-1212-y/fulltext.html> DOI: 10.1186/s12985-019-1212-y *
HIDEYUKI NAKANISHI ET AL: "Comparison oftransposition efficiency between linear and circular donor vectors in mammalian cells", JOURNAL OF BIOTECHNOLOGY, ELSEVIER, AMSTERDAM NL, vol. 154, no. 4, 19 May 2011 (2011-05-19), pages 205 - 208, XP028240752, ISSN: 0168-1656, [retrieved on 20110527], DOI: 10.1016/J.JBIOTEC.2011.05.009 *

Also Published As

Publication number Publication date
IL294926A (en) 2022-09-01
WO2021158565A3 (en) 2021-09-16
JP2023512294A (ja) 2023-03-24
EP4100514A2 (en) 2022-12-14
WO2021158565A2 (en) 2021-08-12
JP2026094336A (ja) 2026-06-09
CA3168836A1 (en) 2021-08-12
MX2022009200A (es) 2023-01-04
BR112022014738A2 (pt) 2022-10-11
AU2021217073A1 (en) 2022-08-18
CN115397998A (zh) 2022-11-25
AU2025287330A1 (en) 2026-01-22
KR20220148823A (ko) 2022-11-07

Similar Documents

Publication Publication Date Title
EP3914259A4 (en) RNA-EDITING OLIGONUCLEOTIDES AND THEIR USE
EP3914260A4 (en) RNA-EDITING OLIGONUCLEOTIDES AND THEIR USE
EP4237107A4 (en) Exercise system
MA49457A (fr) Molécules d&#39;anticorps se liant à cd73 et leurs utilisations
EP4168135A4 (en) STRENGTH TRAINING EQUIPMENT WITH MULTI-CABLE POWER GENERATION
EP3794037A4 (en) ANTI-CLAUDIN 18.2 ANTIBODIES AND USES THEREOF
EP3762031A4 (en) ANTI-CLAUDIN 18.2 ANTIBODIES AND USES THEREFORE
MA54955A (fr) Anticorps anti-claudine 6 et leurs utilisations
EP3735252A4 (en) HETERODUPLEX NUCLEIC ACID MOLECULES AND USES THEREOF
MA50753A (fr) Compositions d&#39;acide nucléique-polypeptide et utilisations de celles-ci
EP4157885A4 (en) Anti-cldn18.2 antibodies and diagnostic uses thereof
EP3938523A4 (en) NON-VIRAL DNA VECTORS AND THEIR USES FOR THE EXPRESSION OF FVIII THERAPEUTICS
EP4054185A4 (en) METHOD AND DEVICE FOR PROCESSING DEEP WHITE BALANCE
EP4132969A4 (en) ANTI-MESOTHELIN ANTIGEN-BINDING MOLECULES AND USES THEREOF
EP1385370A4 (en) ANTIMICROBIAL POLYPEPTIDES AND THEIR USE
EP4222174A4 (en) Antibodies targeting human claudin 18.2 and uses thereof
EP4200414A4 (en) SURFACE AMPLIFICATION COMPOSITIONS AND USES THEREOF
EP4430614A4 (en) Circulating tumor DNA fraction and uses thereof
EP4058572A4 (en) HIGH RESOLUTION SPATIAL AND QUANTITATIVE DNA ASSESSMENT
EP3843790A4 (en) NUCLEIC ACID CONSTRUCTS WITH GENE EDITING MULTI-SITES AND USES THEREOF
EP4262750A4 (en) Protein formulations and uses thereof
EP3717009A4 (en) NUCLEIC ACID BONDING PHOTOS PROBES AND USES THEREOF
EP4267609A4 (en) ANTIBODIES AGAINST HUMAN AND SIMPLE CD3 AND USES THEREOF
EP4352046A4 (en) ISOINDOLINONE COMPOUNDS AND USES THEREOF
EP4281474A4 (en) Dual binding antibodies, methods of producing dual binding antibodies, and uses thereof

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220803

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230601

A4 Supplementary search report drawn up and despatched

Effective date: 20240515

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/245 20060101ALI20240508BHEP

Ipc: A61K 39/215 20060101ALI20240508BHEP

Ipc: A61K 39/12 20060101ALI20240508BHEP

Ipc: C12Q 1/68 20180101ALI20240508BHEP

Ipc: C12N 15/863 20060101ALI20240508BHEP

Ipc: C12N 7/02 20060101ALI20240508BHEP

Ipc: C12N 5/10 20060101AFI20240508BHEP